OPKO Health (OPK) Corporate presentation summary

Strategic growth and value creation

• Advancing a robust therapeutics pipeline with multiple clinical and preclinical assets targeting immuno-oncology, immunology, and metabolic disorders.

• Expanding global pharmaceutical business with sustained sales momentum and specialty products like Rayaldee and NGENLA.

• Streamlining diagnostics operations for profitability, focusing on core clinical testing and the 4Kscore Test.

• Enhanced financial strength through disciplined capital allocation, asset divestitures, and share repurchases.

• Leveraging strategic partnerships to accelerate development and share costs, with significant milestone and royalty opportunities.

Proprietary technology and pipeline

• ModeX platforms enable multispecific antibodies and multivalent nanoparticle vaccines for broad applications.

• Four clinical-stage and five pre-IND assets in immuno-oncology and immunology, including EBV vaccine and tetraspecific T cell engagers.

• Long-acting biologics and peptides in development for hGH, obesity, and metabolic disorders.

• Near-term milestones include multiple Phase 1 trial initiations and data readouts in 2025 and 2026.

Partnerships and market opportunities

• Collaborations with Merck, Regeneron, Pfizer, and Entera Bio provide up to $2B in milestone payments and royalties.

• NGENLA, partnered with Pfizer, is commercialized in 40+ countries and positioned to capture significant share of the $14.3B global hGH market.

• Addressing large, high-need markets in obesity, MASH, and rare diseases, with oral peptide delivery showing favorable data.